MEDROXYPROGESTERONE ACETATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Medroxyprogesterone Acetate, and when can generic versions of Medroxyprogesterone Acetate launch?
Medroxyprogesterone Acetate is a drug marketed by Amneal, Amphastar Pharms Inc, Cipla, Eugia Pharma, Hikma, Hong Kong, Sandoz, Sun Pharm, Teva Pharms Usa, Xiromed, Barr, Duramed Pharms Barr, and Upsher Smith Labs. and is included in sixteen NDAs.
The generic ingredient in MEDROXYPROGESTERONE ACETATE is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Medroxyprogesterone Acetate
A generic version of MEDROXYPROGESTERONE ACETATE was approved as medroxyprogesterone acetate by BARR on August 9th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEDROXYPROGESTERONE ACETATE?
- What are the global sales for MEDROXYPROGESTERONE ACETATE?
- What is Average Wholesale Price for MEDROXYPROGESTERONE ACETATE?
Summary for MEDROXYPROGESTERONE ACETATE
| US Patents: | 0 |
| Applicants: | 13 |
| NDAs: | 16 |
| Finished Product Suppliers / Packagers: | 21 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 123 |
| Patent Applications: | 4,252 |
| Drug Prices: | Drug price information for MEDROXYPROGESTERONE ACETATE |
| What excipients (inactive ingredients) are in MEDROXYPROGESTERONE ACETATE? | MEDROXYPROGESTERONE ACETATE excipients list |
| DailyMed Link: | MEDROXYPROGESTERONE ACETATE at DailyMed |
Recent Clinical Trials for MEDROXYPROGESTERONE ACETATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Rajavithi Hospital | N/A |
| Bezmialem Vakif University | N/A |
| Oregon Health and Science University | Early Phase 1 |
Pharmacology for MEDROXYPROGESTERONE ACETATE
| Drug Class | Progestin |
Medical Subject Heading (MeSH) Categories for MEDROXYPROGESTERONE ACETATE
Anatomical Therapeutic Chemical (ATC) Classes for MEDROXYPROGESTERONE ACETATE
US Patents and Regulatory Information for MEDROXYPROGESTERONE ACETATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amneal | MEDROXYPROGESTERONE ACETATE | medroxyprogesterone acetate | INJECTABLE;INJECTION | 215397-001 | Jun 7, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Duramed Pharms Barr | MEDROXYPROGESTERONE ACETATE | medroxyprogesterone acetate | TABLET;ORAL | 040311-002 | Dec 1, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Hikma | MEDROXYPROGESTERONE ACETATE | medroxyprogesterone acetate | INJECTABLE;INJECTION | 214309-001 | Jan 5, 2023 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
